BTK and acute myeloid leukemia: On the contrary, other BTK inhibitors, such as AVL-292, are in clinical trials for different hematological malignancies such as several B-cell leukemias/lymphomas, myelomas and acute myelogenous leukemia, and autoimmune diseases [29].